DENMARK: Pfizer Inc. has completed its previously announced acquisition of Ferrosan Consumer Health’s business, which includes dietary supplements and the Imedeen skin care range, from Altor 2003 Fund GP Limited.
“Ferrosan Consumer Health’s innovative products and geographic footprint are a strong fit for our business,” said Paul Sturman, president, Pfizer Consumer Healthcare.“Today, we have taken an important step by adding leading brands to our existing portfolio as well as enhancing our presence in established and emerging markets such as the Nordic countries, Russia and Ukraine. Through this acquisition, we’ll have the opportunity to provide a broader portfolio of highly trusted and differentiated products to consumers.”
Headquartered in Copenhagen, Ferrosan Consumer Health today employs approximately 640 people. It has a focused product portfolio of well-established brands including vitamins and probiotics, as well as Imedeen, a leading oral skin care brand.
Also, Pfizer also recently completed its deal for Excaliard Pharmaceuticals, a biopharma company that develops drugs for skin scarring.